AR103355A1 - Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística - Google Patents

Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística

Info

Publication number
AR103355A1
AR103355A1 ARP150104373A ARP150104373A AR103355A1 AR 103355 A1 AR103355 A1 AR 103355A1 AR P150104373 A ARP150104373 A AR P150104373A AR P150104373 A ARP150104373 A AR P150104373A AR 103355 A1 AR103355 A1 AR 103355A1
Authority
AR
Argentina
Prior art keywords
cyclopropanocarboxamide
modulators
driving regulator
transmembrane
chemical fibrosis
Prior art date
Application number
ARP150104373A
Other languages
English (en)
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR103355A1 publication Critical patent/AR103355A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado por la fórmula estructural (1); una sal del mismo, en donde: R¹ - R³ y R⁶ - R²³ se seleccionan independientemente del grupo que consiste en hidrógeno y deuterio; R⁴ - R⁵ se seleccionan independientemente del grupo que consiste en -CH₃, -CH₂D, -CD₂H y -CD₃; y al menos uno de R¹ - R²³ es deuterio o contiene deuterio.
ARP150104373A 2014-12-31 2015-12-30 Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística AR103355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462098735P 2014-12-31 2014-12-31

Publications (1)

Publication Number Publication Date
AR103355A1 true AR103355A1 (es) 2017-05-03

Family

ID=56284953

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104373A AR103355A1 (es) 2014-12-31 2015-12-30 Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística

Country Status (10)

Country Link
US (2) US10167278B2 (es)
EP (1) EP3240539A4 (es)
AR (1) AR103355A1 (es)
AU (1) AU2015374342A1 (es)
BR (1) BR112017014213A2 (es)
CA (1) CA2970948A1 (es)
EA (1) EA201791500A1 (es)
IL (1) IL252818A0 (es)
TW (1) TW201625597A (es)
WO (1) WO2016109362A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
CN109528634A (zh) * 2018-12-19 2019-03-29 江西润泽药业有限公司 复方克林霉素甲硝唑葡萄糖注射液及其制备方法
CN109633040A (zh) * 2019-02-26 2019-04-16 山东博济医药科技有限公司 一种羧甲司坦含量测定方法
CN110227063B (zh) * 2019-06-18 2021-06-15 石药银湖制药有限公司 一种利奈唑胺注射液的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
DK2365972T3 (en) 2008-11-06 2015-01-19 Vertex Pharma Modulators of atp-binding cassette conveyors
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
AU2010310449A1 (en) * 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
PL3835297T3 (pl) 2010-03-25 2023-09-11 Vertex Pharmaceuticals Incorporated Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
US8802868B2 (en) * 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2796646A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CN103153287A (zh) 2010-08-23 2013-06-12 弗特克斯药品有限公司 (R)-1-(2，2-二氟苯并[d][1，3]间二氧杂环戊烯-5-基)-N-(1-(2，3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
HUE047354T2 (hu) * 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP2858645A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators

Also Published As

Publication number Publication date
TW201625597A (zh) 2016-07-16
WO2016109362A1 (en) 2016-07-07
EA201791500A1 (ru) 2018-01-31
US10167278B2 (en) 2019-01-01
US10689370B2 (en) 2020-06-23
IL252818A0 (en) 2017-08-31
EP3240539A4 (en) 2018-07-25
CA2970948A1 (en) 2016-07-07
BR112017014213A2 (pt) 2018-04-10
US20180265501A1 (en) 2018-09-20
EP3240539A1 (en) 2017-11-08
US20190367492A1 (en) 2019-12-05
AU2015374342A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
AR103355A1 (es) Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística
BR112017006253A2 (pt) novos compostos
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
BR112018010118A2 (pt) inibidores de cxcr2
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
BR112017006240A2 (pt) novos compostos
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
EP3686205A8 (en) Method for producing alkali metal sulfate salt
CR20170017A (es) Compuesto heterocíclico
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
AR112787A2 (es) Compuestos 1,5-difenil-penta-1,4-dien-3-ona
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
CR20160202A (es) Procedimiento de preparación de una sal de tipo camsilato
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
TN2017000196A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
AR101036A1 (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
BR112019001305A2 (pt) métodos para produzir ácido acrílico a partir de ácido láctico ou seus derivados em fase líquida
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].

Legal Events

Date Code Title Description
FB Suspension of granting procedure